Molecular biology reports · 2025
Vitamin D3 augments cytotoxic effect of Itraconazole on chronic myelogenous leukemia cell line: a synergic effect on AMPK/AKT signaling pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tahvili Moein, Nejati Vahid, Pazhang Yaghub
Аннотация
BACKGROUND: Growing documents suggest combination therapy as an effective tool to treat the resistant cancer cells. Accordingly, in this study, it has been hypothesized that a combination of Vitamin D3(VD) and Itraconazole can inhibit Chronic Myeloid Leukemia(CML) K562 cells in vitro.
METHODS AND RESULTS: K562 cells were incubated with different concentrations of either VD or Itraconazole either alone or in combination. The results showed that Itraconazole, VD, and combination treatment reduced the cell viability in a time and dose-dependent manner (P < 0.0001). In addition, the apoptosis rate was significantly induced in cells treated with combination drug (P < 0.0001). The Bax/Bcl-2 ratio was increased in treated cells, whereas the subcellular distribution of β-catenin protein was reduced. Morever, the phosphorylation of AKT and p65 were increased, whereas AMPK phosphorylation was decreased in treated cells (P < 0.0001).
CONCLUSION: Our results show that VD and Itraconazole synergically inhibit K562 cells viability via activation of AMPK and suppression of AKT function, suggesting that this combinational therapy potentially benefits CML patients.
METHODS AND RESULTS: K562 cells were incubated with different concentrations of either VD or Itraconazole either alone or in combination. The results showed that Itraconazole, VD, and combination treatment reduced the cell viability in a time and dose-dependent manner (P < 0.0001). In addition, the apoptosis rate was significantly induced in cells treated with combination drug (P < 0.0001). The Bax/Bcl-2 ratio was increased in treated cells, whereas the subcellular distribution of β-catenin protein was reduced. Morever, the phosphorylation of AKT and p65 were increased, whereas AMPK phosphorylation was decreased in treated cells (P < 0.0001).
CONCLUSION: Our results show that VD and Itraconazole synergically inhibit K562 cells viability via activation of AMPK and suppression of AKT function, suggesting that this combinational therapy potentially benefits CML patients.